Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Feb 9, 2015	Biocept, Inc. Prices $10,000,000 Public Offering SAN DIEGO , Feb. 9, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA and circulating tumor cells, today announced the pricing of an underwritten public offering of 8,000,000 shares of its	View HTML Biocept, Inc. Prices $10,000,000 Public Offering 22 KB
Toggle Summary Feb 23, 2015	Study Highlights Value of Biocept's Blood-Based Diagnostic for Determining Hormonal Status in Patients With Metastatic Breast Cancer SAN DIEGO , Feb. 23, 2015 (GLOBE NEWSWIRE) -- Biocept , Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced that its blood-based diagnostic, OncoCEE-BR™, was	View HTML Study Highlights Value of Biocept's Blood-Based Diagnostic for Determining Hormonal Status in Patients With Metastatic Breast Cancer 25.6 KB
Toggle Summary Feb 25, 2015	Biocept, Inc. Schedules Webcast and Conference Call for Fourth Quarter 2014 Financial Results SAN DIEGO , Feb. 25, 2015 (GLOBE NEWSWIRE) -- Biocept , Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced that the Company will issue its financial results for the	View HTML Biocept, Inc. Schedules Webcast and Conference Call for Fourth Quarter 2014 Financial Results 19.6 KB
Toggle Summary Mar 2, 2015	Dr. David Rimm Joins Biocept, Inc. as a Scientific Advisor Yale-Affiliated Pathology and Personalized Medicine Leader to Focus on Assays for Immuno-Oncology Therapies	View HTML Dr. David Rimm Joins Biocept, Inc. as a Scientific Advisor 24.5 KB
Toggle Summary Mar 3, 2015	Biocept to Present at the 27th Annual ROTH Conference SAN DIEGO, March 3, 2015 (GLOBE NEWSWIRE) -- Biocept , Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall, Biocept President and CEO, is scheduled to	View HTML Biocept to Present at the 27th Annual ROTH Conference 10.5 KB
Toggle Summary Mar 5, 2015	Next Generation Sequencing Veteran Joins Biocept Jason Poole, Ph.D. Brings Years of Next Generation Sequencing Experience to the Biocept Research & Development Team	View HTML Next Generation Sequencing Veteran Joins Biocept 24 KB
Toggle Summary Mar 9, 2015	Biocept Reports Fourth Quarter 2014 Financial Results SAN DIEGO, March 9, 2015 (GLOBE NEWSWIRE) -- Biocept , Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced its financial results for the fourth quarter and year ended	View HTML Biocept Reports Fourth Quarter 2014 Financial Results 27.5 KB
Toggle Summary Mar 10, 2015	Biocept Expands Non-Small Cell Lung Cancer Diagnostic Capabilities for EGFR Mutations Adds to Portfolio of Blood-Based 'Liquid Biopsies' With EGFR Mutation Identification to Assist Physicians With Treatment Decisions for Lung Cancer Patients	View HTML Biocept Expands Non-Small Cell Lung Cancer Diagnostic Capabilities for EGFR Mutations 31.2 KB
Toggle Summary Mar 24, 2015	Biocept Enters Clinical Collaboration With University of California, San Diego Moores Cancer Center SAN DIEGO, March 24, 2015 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), today announced that it has entered into a clinical collaboration with	View HTML Biocept Enters Clinical Collaboration With University of California, San Diego Moores Cancer Center 14.3 KB
Toggle Summary May 4, 2015	Biocept Expands Oncology Diagnostic Portfolio With Launch of c-MET Biomarker Biocept's c-MET Test Enables Physicians and Researchers to Identify Key Biomarker From Liquid Biopsy	View HTML Biocept Expands Oncology Diagnostic Portfolio With Launch of c-MET Biomarker 18.9 KB

Investor Relations

Press Releases

Contact Biocept, Inc.